Endo K, Kiyota H, Onodera S
Department of Urology, Jikei University School of Medicine.
Kansenshogaku Zasshi. 1992 Apr;66(4):522-8. doi: 10.11150/kansenshogakuzasshi1970.66.522.
In order to clarify the in vivo effect of the new quinolones in the urinary tract, we investigated the antimicrobial activities against Escherichia coli in the human urine. Human urine was prepared from a normal volunteer. After cations were removed by chelating resin, human urine was supplemented with 50, 100, or 500 micrograms of Mg2+ per ml using MgCl2 or 10, 50, or 150 micrograms of Ca2+ per ml using CaCl2. The pH of human urine was adjusted to 5.5, 7.0, or 8.0 with HCl or NaOH. Four clinical isolates of E. coli and E. coli NIHJ JC-2 were used. And antimicrobial activities of the new quinolones (norfloxacin, enoxacin, ofloxacin and ciprofloxacin) against these strains were measured using various urines as mediums. Antimicrobial activities of the new quinolones were reduced in the presence of high concentration of magnesium or low pH of urine. However, there was no influence of calcium concentration of urine on antimicrobial activities of the new quinolones. From these results, the component of the urine should be checked in the treatment of the patients with urinary tract infection.
为阐明新型喹诺酮类药物在泌尿道中的体内作用，我们研究了其对人尿中大肠杆菌的抗菌活性。人尿取自一名正常志愿者。通过螯合树脂去除阳离子后，用人尿分别添加每毫升50、100或500微克的Mg2+（使用MgCl2）或每毫升10、50或150微克的Ca2+（使用CaCl2）。用人尿的pH值用HCl或NaOH调节至5.5、7.0或8.0。使用了4株大肠杆菌临床分离株和大肠杆菌NIHJ JC-2。并以各种尿液为培养基，测定新型喹诺酮类药物（诺氟沙星、依诺沙星、氧氟沙星和环丙沙星）对这些菌株的抗菌活性。新型喹诺酮类药物的抗菌活性在高浓度镁存在或尿液低pH值时降低。然而，尿钙浓度对新型喹诺酮类药物的抗菌活性没有影响。从这些结果来看，在治疗尿路感染患者时应检查尿液成分。
